LOUIS HARRIS AND ASSOCIATES, INC. 630 Fifth Avenue	/ FOR OFFICE USE ONLY:
New York, New York 10111	Questionnaire No.:
	/
Study No. 861018 (Infectious Diseases)	
July 3, 1986	
s	ample Point No.//////// 10-11-12-13-14
	Time Started:A.M./P.M.
Interviewer:	I.D. No.: Date:
Area Code: Telephone No.:	
	(15-24)
Respondent:	
As you know we are conducting a survey for Brist research. Many of the questions look to the end learn about the developments which you expect to	of this century. We are interested to

· :

	-1-	CARD	1				861018-ID
1. In the year 2000, what do you think w United States and other western industria	ill be th 1 countri	e number es?	one	health	problem	in	the
							_ (25-26)
			· - · · · ·				_ (27-28)
							-
							_
				· · · · · · · · · · · · · · · · · · ·			-
					·		-
			,	·			-
							-
							-
		-,-					_
							_
2. And what do you think will be the numb countries in the year 2000?	ber one he				develop		(29-30)
							(31-32)
		· · · · · · · · · · · · · · · · · · ·		 			
					·		
					·····		

. What do you		-2-	CARD 1	861018-
etween now and	u think should be the nat d the end of the century	tion's number ?	one priority fo	r medical research
			111	(33-34
				(35-36
	-			
·				-
. Smallpox hanink there is	s been eliminated. Are a reasonable chance of o	there any oth ur eliminatin	er diseases or o	conditions which you
				000? Any others?
				000? Any others?
				000? Any others? (37-38
2				000? Any others? (37-38
2				000? Any others? (37-38
2				000? Any others? (37-38
2				000? Any others? (37-38
3				000? Any others? (37-38
3				000? Any others? (37-38
.5				000? Any others? (37-38

	-3-	CARD 1	861018-II
5. Obviously, genetic enginee medicine. If you had to pick will have the greatest impact	a single disease of	r condition on which	ifferent areas of genetic engineering
			(43-44)
			(45-46)
		-	

oa. I Wil	l read you a short list of some of the major areas of r	esearch into in	fectious
diseases.	Please say for each one how promising you think it is	on a scale of 0	to 10
where 0 is	"not promising at all" and where 10 is "most promising	one could imag	ine."
		,	,
1.	New antibiotics	(47-48)	
2.	New systemic antifungal drugs	(49-50)	
3.	New systemic drugs against protozoal parasites	(51-52)	
4.	New antiviral drugs	•	
5.	Treating infections in immunocompromised patients	(53-54)	
6.	Treating reseconded (hearital) infections	(55-56)	
7.	Treating nosocomial (hospital) infections	(57-58)	
,.	Tests, probably based on monoclonal antibodies,		
	that can identify pathogens with high		
•	specificity	(59-60)	
8.	Drugs that are highly specific against a		
_	particular pathogen	(61-62)	
9.	Drug-antibody conjugations	(63-64)	
10.	Passive immunization	(65-66)	
11.	Genetic markers for proneness to certain		
	infections	(67-68)	
12.	Molecular mechanisms of latency, in viruses	()	
	like herpes	(69-70)	
13.	Molecular mechanisms by which pathogens evade	(0) /0)	
	immune surveillance	(71-72)	
14.	Genetically engineered vaccines	(71-72)	
15.	Immunomodifiers and immunostimulants		0.17
13.	Timid Tomod I I I I I I I I I I I I I I I I I I I	(75-76) $77-8$	
		<u>2*(10-1</u>	5)2
6b. Is the promising t	ere any other major area of research into infectious di hat those I have mentioned? If so, what is it? (SPEC	seases which is IFY)	more
6b. Is the promising t	ere any other major area of research into infectious di hat those I have mentioned? If so, what is it? (SPEC	seases which is IFY)	
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is IFY)	more 2*(16-17)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is IFY)	
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is IFY)	
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is IFY)	2*(16-17)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is IFY)	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is IFY)	2*(16-17)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is IFY)	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is IFY)	2*(16-17) (18-19)
6b. Is the	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di hat those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di hat those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di hat those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di hat those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)
6b. Is the promising t	ere any other major area of research into infectious di that those I have mentioned? If so, what is it? (SPEC	seases which is	2*(16-17) (18-19)

					-5	_	CARD 2		861018-II
to	ic resea	arch. W	hat do you	think is	s the mos	t importa	nt fundame	om fundamental ental question treatment of t	n which needs
			,	· · · · · · · · · · · · · · · · · · ·			·· <u>-</u> ·		(22-23)
		7. W							(24-25)
		•					···		
					····				
			1244						

									··
		-							
7b.	If you	had to	guess, when	n do you	think we	will hav	ve the ans	wer to that q	uestion?
			19 / / (26-27)	<u>/</u>	20 /	<u>/_/</u> 28-29)			

						-6-	CARD 2		861	018-ID
						frustration next 14 year	for scientists s?	working in	the	field
									_ (30-31)
							- 44		(32-33)
										
					· · · · · · · · · · · · · · · · · · ·				_	
									_	
									_	
									_	
					~				_	
									_	
			 						_	
			<u>-</u>							
9. bet	Which do	o you thi ention, b	nk will etter d	do th	ne most tasis, or b	o combat infe etter treatme	ectious disease: ent?	s in the yea	ır 2	000
			Better Better	diagno treatm	osis ment	(34(2 3			

10a. I will read you a list of conditions. Please say for each one how much improvement you think we will make by the year 2000 in the <u>prevention</u> of this condition? Please use a scale of 0 to 10 where 0 is "no change" and 10 is "will be prevented entirely."

10b. I will read you a list of conditions again. Please say for each one how much of a change you think we will have made in the <u>treatment</u> of the condition, where 0 is "no change" and where 10 is "will have a total and complete cure by the year 2000."

		Q.10a	Q. 10b
		<u>Prevention</u>	Treatment
1.	Diarrhea	(35-36)	(63-64)
2.	Typhoid fever	(37-38)	(65-66)
3.	Dysentary	(39-40)	(67-68)
4.	Cholera	(41-42)	(69-70)
5.	Hemophilus	(43-44)	
6.	Chlamydia	(45-44)	(71-72)
7.	Malaria	(43-40)	(73-74)
8.	Schistosomiasis	(40-50)	(75-76)
9.	AIDS	(51.50)	(77-78)
10.	Flu.	(51-52)	(79-80)
11.	Colds	(53-54)	3*(10-11)
12.	Slow viruses	(55-56)	(12-13)
13.	Slow viruses	(5/-58)	(14-15)
14.	Herpes	(59-60)	(16-17)
17.	Hepatitis	(61-62)	(18-19)

	-8-		D 3				<u> 361018-I</u>
la. Specifically for malaria, what do yor revention or treatment by the year 2000?	u think w	ill be	the	biggest	advance	in	the
							(20-21
							(22-23
							_
							_
					·		_
							_
							-
							•
			·				•
					·		•
	at do you 00?	think		be the		adv	
b. Specifically for the common cold, who e prevention or treatment by the year 200	at do you 00?	think					(24-25)
b. Specifically for the common cold, who e prevention or treatment by the year 200	at do you 00?	think					(24-25)
b. Specifically for the common cold, who e prevention or treatment by the year 200	at do you 00?	think					(24-25)
b. Specifically for the common cold, whate prevention or treatment by the year 200	at do you 00?	think					(24-25)
b. Specifically for the common cold, who e prevention or treatment by the year 200	at do you 00?	think					(24-25)
b. Specifically for the common cold, who e prevention or treatment by the year 200	at do you 00?	think					(24-25)
b. Specifically for the common cold, who e prevention or treatment by the year 200	at do you 00?	think					(24-25)
b. Specifically for the common cold, who e prevention or treatment by the year 200	at do you 00?	think					(24-25)
b. Specifically for the common cold, who e prevention or treatment by the year 200	at do you	think					(24-25)
b. Specifically for the common cold, who e prevention or treatment by the year 200	at do you	think					(24-25)

) -	CARD	3			86	51018-II
11c. prev	Specifically for ention or treatmen	diarrhea, what the year 2	do you 2000?	think	will be	the	biggest	advance	in	the
										(28-29)
	20.5									(30-31)
								······································		
								 		
								·		
				······						
			-							

CARD 3

12. I will read a list of current and future ways of preventing or diagnosing infectious diseases. Would you please say for each one whether in the year 2000 it will be much more widely used than it is today, somewhat more widely used, less widely used or whether it will scarcely be used at all.

(<u>Prevention a</u>	nd Diagnosis)	Much More Used	Somewhat More Used	Less Used	Used as Often (Vol.)	Scarcely <u>Used</u>	Not Sure
1. Hygiene a measures.	nd sanitary (32(1	2	3	4	5	6
2. Nutrition	(33(1	2	3	4	5 _	6
	l antibody t allow for cific diagnosis(34(1	2	3	4	5 _	6
	s vaccines(3	4	5 _	6
5. Killed vi	rus vaccines(36(1	2	3	4	5 _	6
6. Genetical vaccines.	ly engineered	<u>37(</u> -1	2	3	4	5 _	6
immunoglo	ion with pooled bulins from ors(38(1	2	3	4	5 _	6
clonal or	ion with mono- polyclonal s(<u>39(</u> -1	2	3	4	5	6
	arkers for to certain s(40(1	2	3	4	5	6

13. I will now read a list of current and future ways of treating infectious diseases. Would you please say for each one whether in the year 2000 it will be much more widely used than it is today, somewhat more widely used, less widely used, or whether it will scarcely be used at all.

(<u>Tr</u>	<u>eatment</u>)	Much More Used		Less Used	Used as Often (Vol.)	Scarcely <u>Used</u>	Not Sure
1.	Broad-spectrum antibiotics	(41(1	2	3	4	5	6
2.	Antibiotics that are highly specific for a particular pathogen	(<u>42(</u> -1	2	3	4	5	6
3.	Systemic antifungal drugs	(<u>43(</u> -1	2	3	4	5	6
4.	Systemic drugs against protozoal diseases	(44(1	2	3	4	5	6
5.	Antiviral drugs	(<u>45(</u> -1	2	3	4	5	6
6.	Drugs linked to monoclonal antibodies (to carry the drugs directly to a particular pathogen)			3	4	5	6
7.	Drugs that stimulate the immune system	(<u>47(</u> -1	2	3	4	5	6
8.	Oral rehydration therapy	(48(1	2	3	4	5	6
9.	Nutrition	(<u>49(</u> -1	2	3	4	5	6

		-12- CARD 3	861018-II
14a. types	By the year	ar 200 what do you think will be the 2 or 3 most imports y for infectious diseases which are not available now?	ant, completely new
			(50-51)
			(52-53)
			(54-55)
			<u> </u>
			
· · · · · · · · · · · · · · · · · · ·			
		(these new therapy/therapies) replace or only supplement	nt existing
		(these new therapy/therapies) replace or only supplement Replace(56(1 (ASK Q.14c)	nt existing
			nt existing
	oies?	Replace(<u>56(</u> -1 (ASK Q.14c)	
	oies?	Replace(56(1 (ASK Q.14c) Supplement2 Not sure3 (SKIP TO Q.15) Can you think of a specific treatment which will be reported.	placed and, if so,
	oies?	Replace(<u>56(1</u>	placed and, if so,
	oies?	Replace(56(1 (ASK Q.14c) Supplement2 Not sure3 (SKIP TO Q.15) Can you think of a specific treatment which will be repat? (PROBE: What will replace what?)	placed and, if so, (57-58
	oies?	Replace(56(1 (ASK Q.14c) Supplement2 Not sure3 (SKIP TO Q.15) Can you think of a specific treatment which will be reat? (PROBE: What will replace what?)	placed and, if so, (57-58
	oies?	Replace(56(1 (ASK Q.14c) Supplement2 Not sure3 (SKIP TO Q.15) Can you think of a specific treatment which will be reat? (PROBE: What will replace what?)	placed and, if so, (57-58
14b. therap	oies?	Replace(56(1 (ASK Q.14c) Supplement2 Not sure3 (SKIP TO Q.15) Can you think of a specific treatment which will be reat? (PROBE: What will replace what?)	placed and, if so, (57-58
	oies?	Replace(56(1 (ASK Q.14c) Supplement2 Not sure3 (SKIP TO Q.15) Can you think of a specific treatment which will be reat? (PROBE: What will replace what?)	placed and, if so, (57-58
	oies?	Replace(56(1 (ASK Q.14c) Supplement2 Not sure3 (SKIP TO Q.15) Can you think of a specific treatment which will be reat? (PROBE: What will replace what?)	placed and, if so, (57-58

es est

	-13-	CARD	3		361018-ID
18a. What infectious diseases in priority for research over the nex	the developing t 14 years?	countries	do you	think should be	e <u>the</u> top
					_ (66-67)
					_
					_
					
					_
					_
					-
					_
					_
					_
					_

•

	-14-	CARD 3/4	86	51018-ID
18b. What infectious disease in the Unite should be <u>the</u> top priority for research or	ed States ar	nd the developed : 14 years?	world do you	think
				(70-71)
				(72-73)
			1	
		111		•
the figure is likely to be in the year 20 $\frac{,000}{4*(40-45)}$				
Not sure(46(1			
19b. By what year do you think a safe an generally available?	nd effective	vaccine against	AIDS will be	3
19 / / / (7	74-75)			
20 /_/_/ (7	76-77)			
Not sure(78(1		79-80Z	
			77 002	
19c. By what year do you think an effect	tive cure fo	or AIDS will be a	generally ava:	ilable?
19 / / /4*(10-11)			
20 /_ /_ / (12-13)			
Not sure(14(1			
			<u> 15-18Z</u>	

.

CARD 4

21a. Finally a question on life expectancy. The life expectancy of men and women in the United States is about 71 and 78 respectively. What is your best guess for what the life expectancy of men and women in the U.S. will be in the year 2000? RECORD BELOW

21b. Do you think there is any limit to how much we can increase the human life span, or do you think that we can go on increasing it indefinitely?

There is a limit.....(33(____-1 (ASK Q.21c)

21c. What do you think that limit is for men? For women? RECORD BELOW

47-80Z

That completes the interview. Thank you very much for your cooperation!

AFTER THANKING RESPONDENT:

As our letter to you indicated, we will send you a copy of the report as soon as it is ready. Your name will be included in the list of the people interviewed at the back of the report. However, I would like to confirm that only aggregate data will be included and no responses will be attributed to you or any other individuals.

TIME ENDED:	Α.	M.	/	P	•	M	
-------------	----	----	---	---	---	---	--